Skip to main content

Table 1 Esophagus

From: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis

Author Cases n Controlsa/Cohortb Source population Exposure definition Exposure assessment Drug RR 95% CI
Coogan et al. [26] 207 5,833a Hospital based >4 days/week for >3 months. Continuing use during 1 year of lag time Personal Interview NSAIDs (7%) 0.8 0.5–1.4
Farrow et al. [30] 277 687a Population based >1 tablet/week during >6 months. 1 year lag time Personal Interview Aspirin (31%) 0.48 0.32–0.70
  279      NA-NSAIDs (13%) 0.81 0.51–1.30
Langman et al. [36] 550 1,650a Population based >7 prescriptions during months 13–36 before index date Automated Database NSAIDs (8%) 0.64 0.41–0.98
Garidou et al. [32] 56 200a Hospital based Chronic intake Personal Interview NSAIDs (14%) 0.52 0.17–1.62
Suleiman et al. [59] 56 56a Population based Ever use for >1 year Medical records NSAIDs (38%) 0.16 0.03–0.93
Cheng et al. [60] 74 74a Population based Ever daily use for >1 month Personal Interview Aspirin (21%) 0.67 0.27–1.63
Funkhouser et al.31 15 13,179b Cohort Use 30 days before baseline (ocasional) Personal Interview Aspirin (51%) 0.10 0.01–0.76
Thun et al. [46] 157 635,031b Cohort More than 16 times per month for at least one year Mailed questionnaire Aspirin (11%) 0.59 0.34–1.03
  1. Prevalence of exposure among controls/cohort; Adenocarcinoma.